-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
374Water Reports 83% Year-Over-Year Revenue Growth for the First Nine Months of 2026
-
GRID Alternatives and Climate First Bank Partner to Expand Access to Solar Financing in the Mid-Atlantic
-
First Breach Reports Third Quarter 2026 Results
-
Envela Reports Third Quarter 2026 Financial Results
-
FarmBot Tech Taps Dr. Luca Brillante, a Pioneer of Precision Viticulture, as Founding Chief Technology Agronomist
-
Vulcan Infrastructure and Power Reports Third Quarter 2026 Results
-
DataMEDS AI Releases CEO Letter
-
Ensysce Biosciences Announces Participation in Upcoming Investor Conferences
-
Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results
-
Blue Dolphin Reports Third Quarter 2026 Financial Results
-
Healthy Extracts Reports Results for Third Quarter and Nine Months 2026
-
Rosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender Offer
-
Smith-Midland Reports Third Quarter 2026 Financial Results
-
NextBoat Inc. Announces Fiscal Third Quarter 2026 Results
-
Epomaker BFCM Deals and New Product Launches Are Here
-
Rusty Taco Expands Commitment to Local Communities Through New Force4Good Partnership
-
Kidoz Inc. to Publish Q3 2026 Financial Results on Thursday, November 19, 2026, and Hold AGM on Tuesday, November 24, 2026
-
SMX Brings American Ingenuity to the Next Frontier of Artificial Intelligence
-
CORRECTION FROM SOURCE: Sekur Private Data Ltd. Provides Update on Expected Closing of Non-Brokered Private Placement
-
Sebring Design Build Wins Best Universal Design in the 2026 KBB Awards for a Franklin Primary Bath
-
SMX Puts American Innovation to Work in the New Era of Artificial Intelligence
-
Convergence Family Office Salon Announces 2027 Annual Gathering in Utah and Expansion to Dallas, Orange County and Kansas City
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Capital Market maintain a minimum bid price of $1.00 per share, and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. Nasdaq also notified the Company in the Compliance Notice that the hearing before the Nasdaq Hearings Panel previously scheduled to take place on July 15, 2025, has been cancelled, and the Company's securities will continue to be listed and traded on The Nasdaq Capital Market.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company with over 20 years of experience in developing and commercializing polymerase chain reaction (PCR)-based applications for DNA production. Through its majority-owned subsidiary, LineaRx Inc., the Company is commercializing its LineaDNA and LineaIVT platforms to enable the manufacture of next-generation nucleic acid-based therapies.
Visit adnas.com for more information. Follow us on X and LinkedIn.
Forward-Looking Statements
The statements made by Applied DNA Sciences in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from those projected due to the Company's history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future ability to continue its listing on the Nasdaq Capital Market, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our LineaDNA and/or LineaIVT platforms, the fact that there has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or LineaIVT platforms, as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Applied DNA Sciences Contact:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]
Web: https://investors.adnas.com
SOURCE: Applied DNA Sciences, Inc.
View the original press release on ACCESS Newswire
H.Romero--AT